Social Development

Policy Brief 56, October 2018

Setting the pillars to enforce corporate human rights obligations stemming from international law

The release of the Zero Draft of the Legally Binding Instrument to Regulate, in International Human Rights Law, the Activities of Transnational Corporations and other Business Enterprises by the Chairperson of the Open-ended Intergovernmental Working Group on Business and Human Rights (OEIGWG), is likely to revive discussions on the recognition of corporate entities as subjects of international law. The present brief examines corporate entities’ human rights obligations in the context of the Zero Draft, taking into account the views and comments presented during the first three sessions of the OEIGWG and the need to advance the discussion on those entities’ obligations under international law.

(more…)

Policy Brief 55, October 2018

Advancing international cooperation in the service of victims of human rights violations in the context of business activities

A zero draft of a legally binding instrument to regulate, in international human rights law, the activities of transnational corporations and other business enterprises, is the subject of discussions in an inter-governmental open ended working group under the auspices of the Human Rights Council (15-19 October 2018). The draft aims at harnessing international cooperation among home and host states of business enterprises in order to address barriers  to get remedies to victims of human rights violations  in the context of business activities of transnational character. This brief discusses the approach to States’ role and obligations as proposed under the zero draft.

(more…)

Policy Brief 54, October 2018

The Use of TRIPS Flexibilities for the Access to Hepatitis C Treatment

In late 2013, a new Hepatitis C treatment called direct-acting antivirals (DAAs) was introduced in the market at unaffordable prices. The eradication of the disease is possible if medicines can be purchased at AFFORDABLE prices within health budgets. IF THIS IS NOT THE CASE, governments should consider the use of the TRIPS flexibilities to facilitate access to the treatment.

(more…)

Statement, September 2018

Statement by the South Centre to the Nelson Mandela Peace Summit

At the Nelson Mandela Peace Summit , the South Centre highlighted Nelson Mandela’s battle against apartheid, which was a main obstacle to social development, and against actions by pharmaceutical companies to enforce intellectual property standards that would prevent access to HIV/AIDS drugs.

(more…)

Statement, September 2018

Statement by the South Centre to the Third High-Level Meeting on the Prevention and Control of Non-Communicable Diseases

Below is the statement by the South Centre to the Third High-Level Meeting on the Prevention and Control of Non-Communicable Diseases (NCDs) during the 73rd session of the United Nations (UN) General Assembly held on 27 September 2018 at the UN headquarters in New York.

(more…)

Statement, September 2018

Statement by the South Centre at the High Level Meeting on the Fight to End Tuberculosis

Below is the South Centre statement at the High Level Meeting on the Fight to End Tuberculosis during the 73rd session of the United Nations (UN) General Assembly held on 26 September 2018 at the UN headquarters in New York.

(more…)

Policy Brief 53, September 2018

Considerations for the Effective Implementation of National Action Plans on Antimicrobial Resistance

Effective design and implementation of national action plans (NAPs) is critical for the response to the growing challenge of antimicrobial resistance (AMR).  This policy brief describes the messages that the South Centre has transmitted to the United Nations Inter-Agency Coordination Group (IACG) on AMR in the context of its public consultation, towards shaping its recommendations that will be submitted to the United Nations Secretary-General in the second half of 2019.

(more…)

SC WTO Public Forum Event, 2 October 2018

Title:                             Intellectual Property and Health: The Use of TRIPS Flexibilities to Achieve                                                    SDGs

Date and Time:            2 October 2018, 11:30-13:00

Venue:                          Room S1, The World Trade Organization (WTO), Geneva

Organizer:                   The South Centre

(more…)

Announcement, September 2018

New project to scale up access to medicines 

The South Centre is pleased to announce that it is scaling up its services to developing country governments in the area of intellectual property rights and public health, thanks to the support of Unitaid. The project “Expanding the use of TRIPS flexibilities to promote affordable access to medicines” will allow the South Centre to roll out a number of training activities at regional and national level and a global advisory service on the use of TRIPS flexibilities for public health.

(more…)

Analytical Note, September 2018

Towards the Adoption of a UN Declaration on the Rights of Peasants and Other People Working In Rural Areas

The UN Declaration on the Rights of Peasants and Other People Working in Rural Areas has been constructed by an Open-ended Intergovernmental Working Group over six years of open and transparent negotiations. The text has significant support from members of the Human Rights Council. Accordingly, member States of the Human Rights Council should adopt the  Declaration through an upcoming Resolution at the 39th Human Rights Council Session (10-28 September 2018).

(more…)

WTO Public Forum, October 2018

Title:              WTO Rules for Ensuring Sustainable Agriculture and  Food Security: An SDG Compatibility Analysis

Date:              3 October 2018

Venue:           The World Trade Organization, Geneva

Organizer:     Third World Network (TWN) India, Bangladesh Krishok Federation, More and Better Network 

(more…)

Policy Brief 50, August 2018

The International Debate on Generic Medicines of Biological Origin

The debate on generic medicines is not new. What makes it different today is that attacks levelled against biological generic products are couched in even more “technical” and abstruse language. The high price of biological drugs stems mainly from the introduction of barriers to the entry of generics into the market. In any debate on the feasibility of producing biological generic products identical to the ‘original’ ones, it should be made clear that what are at stake are not identical products but therapeutic equivalents.

(more…)


0

Your Cart